Core Viewpoint - The company intends to purchase Directors and Officers Liability Insurance (D&O Insurance) to enhance governance and risk management, ensuring the protection of the company and its stakeholders [1][2]. Group 1: D&O Insurance Proposal - The insurance will cover the company and all directors, senior management, and relevant responsible personnel, with a compensation limit of up to RMB 50 million [1]. - The estimated insurance cost will not exceed RMB 250,000, and the insurance period is set for one year, with options for renewal or reinsurance [1]. Group 2: Authorization Matters - The board will seek authorization from the shareholders' meeting to allow the board and its authorized personnel to handle the insurance purchase, including determining responsible parties, selecting the insurance company, and signing relevant legal documents [1][2]. Group 3: Impact on the Company - The purchase of D&O Insurance aligns with the requirements of the Company Law and the Corporate Governance Code, providing essential protection for directors and senior management, which is expected to enhance management team motivation and promote high-quality company development [2]. - The anticipated insurance costs are within a reasonable market range and will not significantly impact the company's financial status or harm the interests of shareholders, particularly minority shareholders [2].

Core Points - The company held its fifth board meeting of 2025 on August 13, 2025, with all nine directors present, complying with relevant laws and regulations [1] - The board approved the 2025 semi-annual report under Chinese standards and the interim report under international standards, with unanimous support [1] - A special report on the use of raised funds was also approved, receiving full agreement from the board [1] - The board reviewed and approved a risk assessment report regarding Tianjin Pharmaceutical Group Finance Co., Ltd., with unanimous support [1] - The board approved a proposal to purchase liability insurance for the company and its directors, supervisors, and senior management, which will be submitted to the shareholders' meeting for approval [2] - The board also approved amendments to the general authorization for related party transactions according to Singapore Exchange rules, which will be submitted to the shareholders' meeting for approval [2]